CN110339323A - 一种治疗心动过缓的中药组合物及其制备方法和应用 - Google Patents
一种治疗心动过缓的中药组合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN110339323A CN110339323A CN201910679630.9A CN201910679630A CN110339323A CN 110339323 A CN110339323 A CN 110339323A CN 201910679630 A CN201910679630 A CN 201910679630A CN 110339323 A CN110339323 A CN 110339323A
- Authority
- CN
- China
- Prior art keywords
- parts
- grams
- radix
- chinese medicine
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 75
- 230000036471 bradycardia Effects 0.000 title claims abstract description 38
- 208000006218 bradycardia Diseases 0.000 title claims abstract description 36
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- OEYQBKYISMRWQB-UHFFFAOYSA-N Santal Chemical compound C=1C(OC)=CC(O)=C(C2=O)C=1OC=C2C1=CC=C(O)C(O)=C1 OEYQBKYISMRWQB-UHFFFAOYSA-N 0.000 claims abstract description 52
- 241000758794 Asarum Species 0.000 claims abstract description 25
- 241000218671 Ephedra Species 0.000 claims abstract description 25
- 235000011996 Calamus deerratus Nutrition 0.000 claims abstract description 22
- 229940079593 drug Drugs 0.000 claims description 39
- 244000205574 Acorus calamus Species 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 210000002826 placenta Anatomy 0.000 claims description 9
- 108010010803 Gelatin Proteins 0.000 claims description 8
- 229920000159 gelatin Polymers 0.000 claims description 8
- 239000008273 gelatin Substances 0.000 claims description 8
- 235000019322 gelatine Nutrition 0.000 claims description 8
- 235000011852 gelatine desserts Nutrition 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 239000006187 pill Substances 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 241000208340 Araliaceae Species 0.000 claims description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 2
- 235000008434 ginseng Nutrition 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims 1
- 210000002216 heart Anatomy 0.000 abstract description 50
- 239000008280 blood Substances 0.000 abstract description 37
- 210000004369 blood Anatomy 0.000 abstract description 34
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 16
- 208000026435 phlegm Diseases 0.000 abstract description 16
- 206010040738 Sinus arrest Diseases 0.000 abstract description 7
- 208000031975 Yang Deficiency Diseases 0.000 abstract description 6
- 208000024891 symptom Diseases 0.000 abstract description 6
- 230000001976 improved effect Effects 0.000 abstract description 3
- 240000008167 Calamus deerratus Species 0.000 abstract 1
- 208000028347 Sinus disease Diseases 0.000 abstract 1
- 230000008506 pathogenesis Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 23
- 201000010099 disease Diseases 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 230000006870 function Effects 0.000 description 13
- 210000004072 lung Anatomy 0.000 description 12
- 230000001737 promoting effect Effects 0.000 description 12
- 208000002193 Pain Diseases 0.000 description 11
- 230000004087 circulation Effects 0.000 description 11
- 230000036407 pain Effects 0.000 description 10
- 210000002784 stomach Anatomy 0.000 description 9
- 230000017531 blood circulation Effects 0.000 description 8
- 208000002173 dizziness Diseases 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 235000009508 confectionery Nutrition 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 238000010792 warming Methods 0.000 description 6
- 206010040741 Sinus bradycardia Diseases 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 210000001367 artery Anatomy 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 235000012907 honey Nutrition 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- 206010003671 Atrioventricular Block Diseases 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- 206010040639 Sick sinus syndrome Diseases 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 3
- 206010040736 Sinoatrial block Diseases 0.000 description 3
- 230000002567 autonomic effect Effects 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 206010042772 syncope Diseases 0.000 description 3
- 230000001515 vagal effect Effects 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 229930003347 Atropine Natural products 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 102100031939 Erythropoietin Human genes 0.000 description 2
- 206010016807 Fluid retention Diseases 0.000 description 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 206010000059 abdominal discomfort Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 206010001902 amaurosis Diseases 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000003288 anthiarrhythmic effect Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 2
- 229960000396 atropine Drugs 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000005059 dormancy Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical group Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000173529 Aconitum napellus Species 0.000 description 1
- 206010001115 Adams-Stokes syndrome Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 206010049765 Bradyarrhythmia Diseases 0.000 description 1
- 241000269420 Bufonidae Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000009084 Cold Injury Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 241000208296 Datura Species 0.000 description 1
- 206010057315 Daydreaming Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 240000001879 Digitalis lutea Species 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010017999 Gastrointestinal pain Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ALHUZKCOMYUFRB-OAHLLOKOSA-N Muscone Chemical compound C[C@@H]1CCCCCCCCCCCCC(=O)C1 ALHUZKCOMYUFRB-OAHLLOKOSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010029470 Nodal rhythm Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 1
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 206010042602 Supraventricular extrasystoles Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 210000003056 antler Anatomy 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000008845 cholagoga Substances 0.000 description 1
- 229940124571 cholagogue Drugs 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 230000002595 cold damage Effects 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 208000024756 faint Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000008473 mahuang fuzi xixin Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- ALHUZKCOMYUFRB-UHFFFAOYSA-N muskone Natural products CC1CCCCCCCCCCCCC(=O)C1 ALHUZKCOMYUFRB-UHFFFAOYSA-N 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 210000001013 sinoatrial node Anatomy 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical class O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 238000013022 venting Methods 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
- A61K36/268—Asarum (wild ginger)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/808—Scrophularia (figwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种治疗心动过缓的中药组合物及其制备方法和应用,包括以下重量份的各组分,桂枝10~20份,菖蒲10~30份,郁金10~30份,炙麻黄6~15份,细辛2~6份,木香6~20份,檀香3~10份和炙甘草6~20份。诸药配伍共奏温心阳、散寒滞、祛痰浊、益气血之功,能够提高心率,减少长间歇,改善症状,用于治疗心阳不振、痰瘀互结为主要病机的窦缓、传导阻滞、窦性停搏与病窦疗效显著。
Description
技术领域
本发明涉及一种治疗心动过缓的药物组合物,具体而言,涉及一种治疗心动过缓的药物组合物及其制备方法和应用。
背景技术
心动过缓(bradyarrhythmia,BA)是指有效心搏低于60次/分,包括窦性心动过缓、病态窦房结综合征、窦性停搏、窦房传导阻滞、房室传导阻滞。窦性心动过缓可见于健康的成年人、运动员与睡眠状态,其他原因包括颅内疾患、严重缺氧、低温、甲状腺功能减退等,亦可致窦性心动过缓。心肌病变、冠脉血流异常及迷走神经张力增高等,可致传导阻滞、窦性停搏。应用洋地黄、β受体阻滞剂、维拉帕米、地尔硫卓等药物,或心肌硬化与退行性变、淀粉样变性、纤维化与脂肪浸润等损害窦房结,可导致病态窦房结综合征。
心动过缓可出现心、脑等脏器供血不足的症状,如头晕、乏力、黑矇等,严重者可发生阿-斯综合征或心源性猝死。目前现代医学治疗心动过缓的药物主要有胆碱能受体阻断剂(阿托品)、β受体激动剂(异丙肾上腺素)和茶碱类(氨茶碱)等,但这些药物本身临床适应证并非针对心动过缓,其提高心率的效果只是药物的次要作用,且多存在许多副作用,不宜长期使用。如阿托品可引起口干、便秘、尿潴留及视物模糊等,异丙肾上腺素有诱发室性心律失常的风险。此外,对于心律矛盾的慢-快综合征,往往会产生用药困难。对于有症状的心动过缓,西医多安装心脏起搏治疗,但国内往往因为经济、患者接受意愿、基层医疗环境与技术问题等因素而受到限制。而对于有症状、不愿安装起搏器或存在手术禁忌症的患者,本方可显著提高心率,减少长间歇,平衡自主神经功能,改善临床症状,治疗心动过缓。
发明内容
为解决上述问题,本发明提供一种中药组合物及其制备方法和应用,所述中药组合物用于治疗心动过缓,所述心动过缓包括窦性心动过缓、病态窦房结综合征、窦性停搏、窦房传导阻滞、房室传导阻滞。
本发明的技术方案是:
一种治疗心动过缓的中药组合物,包以下重量份的各组分,桂枝 10~20份,菖蒲10~30份,郁金10~30份,炙麻黄6~15份,细辛2~6 份,木香6~20份,檀香3~10份和炙甘草6~20份。
所述的桂枝10份,菖蒲20份,郁金20份,细辛3份,木香10份,檀香10份,炙麻黄10份和炙甘草10份。
还包括丹参10~30份,玄参10~20份,阿胶10~20份、紫河车6~ 10份。
在该中药组合物内加上药学上可接受的赋形剂制成药学上的常规制剂。
所述赋形剂位崩解剂、润滑剂或黏合剂中的一种或多种,所述药学上的常规制剂优选汤剂、丸剂、散剂、膏方、胶囊或片剂的口服制剂。
一种治疗心动过缓的中药组合物在制备治疗心动过缓的药物中的应用。
一种制备治疗心动过缓的中药组合物的方法,包括如下步骤:
(1)将各组分按照重量比称重;
(2)将步骤(1)中混合的各组分混合并置于容器内,加水没过药面,浸泡20~30分钟;
(3)用文火煎煮,至煮沸后再继续煎煮20~30分钟,共煎煮三次;
(4)将三次煎液合并、过滤,得到汤剂。
所述的步骤(3)中,煎煮时间为25分钟。
以下为各组分的作用和功效:
桂枝:辛、甘,温。归心、肺、膀胱经。具有发汗解肌,温通经脉,助阳化气之功。可用于胸阳不振,心脉痹阻,胸痹心痛,心动悸、脉结代者。研究表明,桂枝可明显增加心动过缓大鼠的心率,还能改善冠脉循环,保护心肌细胞。
菖蒲:辛、苦,温。归心、胃经。具有开窍醒神,宁神益志,化湿和胃的功效。适用于失眠健忘、痰蒙清窍、热病神昏等症。现代药理研究表明其挥发油能够抑制异位起搏点,具有抗心律失常的作用,还能够降脂、解痉。
郁金:辛、苦,寒,归肝、心、肺经。功能活血止痛,行气解郁,清心凉血,利胆退黄。适用于气滞血瘀诸痛、血热妄行、痰热闭阻等症。现代药理研究表明其水煎剂具有降低全血粘度,抑制血小板聚集的作用;还具有降脂,抗炎止痛,保护肝细胞等作用。
炙麻黄:辛、微苦,温。归肺、膀胱经。功效发汗解表,宣肺平喘,利水消肿。用于风寒感冒,咳嗽气喘,风水水肿等症。现代研究表明,其成分麻黄碱可作用于心肌细胞离子通道,兴奋心肌细胞,增强心肌收缩力,提高心率,还有解热、抗炎的作用。
细辛:辛,温。有小毒。归肺、肾、心经。具有解表散寒,祛风止痛,温肺化饮之功。适用于阳虚外感,寒湿痹痛,水饮内停咳喘之症。现代药理研究表明,其提取物有强心,舒张血管,改善心肌缺血,降压,抗血小板聚集,解热,抗炎,镇静等功效。
木香:辛、苦,温。归脾、胃、大肠、胆、三焦经。功效行气止痛,健脾消食。可用于治疗气滞、寒凝、血瘀之胸痹心痛,饮食积滞诸症。现代研究表明木香提取物具有扩张血管,降压,解痉镇痛,抗炎,抗氧化,促胃动力,利胆等作用。
檀香:辛,温。归脾、胃、心、肺经。具有行气止痛,散寒调中之功。用于寒凝气滞,胸腹冷痛之症。现代药理研究表明,檀香液对四逆汤、五加皮中毒所致心律失常具有拮抗作用,对小鼠中枢具有镇静作用,还可缓解肠道痉挛,调节胃肠道功能。
炙甘草:甘,平。归心、肺、脾、胃经。功效补脾益气,祛痰止咳,缓急止痛,调和诸药。可用于心气不足,心动悸、脉结代,脾气虚弱,咳喘,四肢挛急诸症。现代研究表明,炙甘草具有抗心律失常,镇咳平喘,镇痛,抗炎等作用。
阿胶:甘,平。入肺、肝、肾经。功能补血滋阴,润燥,止血。治眩晕心悸,心烦不眠,虚风内动等。药理研究表明阿胶能改善血液流变性和微循环,可明显延长内毒素休克动物的存活时间,降低死亡率;还可升高红细胞、血红蛋白。
紫河车:甘、咸,温。归肺、肝、肾经。功效补肾益精,养血益气。治疗气血不足,头晕耳鸣,腰酸乏力诸症。药理研究表明,紫河车提取物含有多种抗体、红细胞生成素、蛋白质、氨基酸、微量元素等,具有增强机体免疫力、抗过敏、抗感染、抗病毒等作用。
丹参:苦,微寒。归心、心包、肝经。具有活血祛瘀,凉血消痈,清心除烦的功效。适用于血瘀生热所致的心悸怔忡、失眠等症。现代研究表明丹参具有扩张冠脉,增加冠脉血流量,改善微循环,抗血栓形成,促进组织的修复与再生,降血脂等作用。
玄参:甘、苦、咸,微寒。归肺、胃、肾经。凉血滋阴,泻火解毒。适用于热病伤阴,舌绛烦渴,津伤便秘,目赤咽痛等。现代研究表明玄参可对抗垂体后叶素所致的冠脉收缩,具有改善心肌供血,强心,扩张外周血管,降压,镇静等作用。
心动过缓根据其临床症状归属于祖国医学中“心悸”、“迟脉”范畴。心藏神,主血脉,为“五脏六腑之大主”,主宰人体的生命活动。《濒湖脉学》日:“迟来一息至惟三,阳不胜阴气血寒。”心为阳中之太阳,以阳气为用。年老久病、劳倦过度耗损心阳,或感受寒邪、贪凉饮冷伤及心阳,致心阳不振,无力推动血液运行,产生心悸、胸闷、气短、脉缓等症。嗜食肥甘、好烟嗜酒,损伤脾胃,运化失健,聚湿生痰;或平素精神紧张、情志不舒,气血运行不畅,气滞血瘀,或阳虚则寒,血脉凝滞,致痰瘀痹阻血脉,使脉管狭窄、滞涩,诱发胸闷、胸痛、脉来迟涩等症。年老气血渐亏,或先天不足,精血衰少,脉道无以充养,脏腑、形体、官窍失于濡养,导致头晕、乏力等症。可以看出,心阳不振、痰瘀痹阻,使心脏调控血脉及脏腑的功能发挥失常,产生心悸、胸闷、胸痛、气短、头晕、乏力、脉来迟滞等症,严重者甚至出现黑矇、晕厥。心动过缓以心阳虚衰为本,气滞、痰浊、血瘀互结为标,治疗当以温通心阳、理气活血、化痰祛瘀为法。
桂枝辛温,归心、肺经,助阳化气、温振心阳为君药。心阳不振,阴寒偏盛,易于形成痰饮水湿,还可使血脉收引、凝滞导致血瘀,故当注重温补阳气,兼以祛邪。寒凝、气滞、痰浊、血瘀常相兼为患,因此散寒、化痰、活血、行气四者应当并用。菖蒲、郁金寒温并用,化痰开窍,行气解郁,活血止痛;炙麻黄、细辛取麻黄附子细辛汤之意,功能温阳散寒、宣通气血、蠲痹通滞,具有出里走表、达卫散寒、伸发阳气之功,共为臣药。木香辛温,行气止痛,健脾以助运化;檀香温中散寒,助桂枝温振心阳,且有活血止痛之功,用为佐药。炙甘草为使药,一则调和诸药,二来可益气复脉。痰瘀日久易于化热,症见心悸、怕热者,配伍养血活血、滋阴清热之丹参、玄参。若虚损较重,气血衰弱,失于濡养,见乏力、口干,加血肉有情之品阿胶、紫河车补益气血。诸药配伍,共奏温阳散寒、化痰祛瘀之功,主治心阳不振、痰瘀互结之心动过缓。
本发明中药组合物还可加上药学上可接受的赋形剂制成药学上的常规制剂,所述赋形剂包括崩解剂、润滑剂、黏合剂等,所述药学上的常规制剂优选包括口服药制剂;其中,口服药制剂包括汤剂、丸剂、散剂、膏方、胶囊或片剂等。
本发明的另一个目的,还提供一种中药组合物在制备治疗心动过缓的药物中的用途,所述心动过缓包括窦性心动过缓、病态窦房结综合征、窦性停搏、窦房传导阻滞、房室传导阻滞。
此外,本发明制备的中药组合物进行了临床有效性及安全性观察试验。试验证明本发明药物能够显著提高心率,减少长间歇,降低迷走神经张力,平衡自主神经功能,治疗心阳不振、痰瘀互结证心动过缓安全、有效。
具体实施方式
下面结合具体实施例对本发明作进一步详细描述,但不作为对本发明的限定。
实施例1:桂枝10克、菖蒲10克、郁金10克、炙麻黄6克、细辛2克、木香6克、檀香3克和炙甘草6克。
将上述原料药物混合在一起,置于砂锅内,加水没过药面,浸泡 20~30分钟后用文火煎煮,煮沸后再继续煎煮30分钟,共煎煮三次,合并三次煎液过滤得到汤剂。使用指导:汤剂,每日一剂、水煎服,早晚各一次,28天为一疗程。
实施例2:桂枝12克、菖蒲20克、郁金20克、炙麻黄10克、细辛6 克、木香12克、檀香6克和炙甘草12克。
制备服用方法如实施例1。
实施例3:桂枝15克、菖蒲15克、郁金15克、炙麻黄9克、细辛6克、木香15克、檀香9克和炙甘草15克。
制备服用方法如实施例1。
实施例4:桂枝10克、菖蒲20克、郁金20克、炙麻黄10克、细辛3 克、木香10克、檀香10克和炙甘草10克。
制备服用方法如实施例1。
实施例5:桂枝15克、菖蒲30克、郁金30克、炙麻黄12克、细辛5 克、木香20克、檀香10克和炙甘草20克。
制备服用方法如实施例1。
实施例6:桂枝10克、菖蒲20克、郁金20克、炙麻黄10克、细辛3 克、木香15克、檀香6克、炙甘草6克、丹参10克和玄参10克。
制备服用方法如实施例1。
实施例7:桂枝12克、菖蒲20克、郁金20克、炙麻黄12克、细辛6 克、木香10克、檀香10克、炙甘草12克、丹参20克、玄参20克、阿胶12 克。
制备服用方法如实施例1。
实施例8:桂枝15克、菖蒲15克、郁金15克、炙麻黄9克、细辛3克、木香12克、檀香9克、炙甘草9克、丹参20克、玄参15克、紫河车9克。
制备服用方法如实施例1。
实施例9:桂枝12克、菖蒲12克、郁金12克、炙麻黄6克、细辛3克、木香9克、檀香6克、炙甘草6克、丹参10克、玄参10g、阿胶10克和紫河车6克。
制备服用方法如实施例1。
实施例10:桂枝20克、菖蒲30克、郁金30克、炙麻黄15克、细辛6 克、木香15克、檀香10克、炙甘草15克、阿胶15克和紫河车10克。
散剂包括如下步骤:
(1)将上述原料药物混合在一起;
(2)将上述中药组分干燥后磨粉,药物粉末为60~100目为宜;
(3)将药物粉末分装,得到散剂。
实施例11:桂枝15克、菖蒲15克、郁金15克、炙麻黄12克、细辛6 克、木香10克、檀香9克和炙甘草12克。
水丸剂包括如下步骤:
(1)将上述原料药物混合在一起;
(2)将上述中药组分干燥后磨粉,药物粉末为60~100目为宜;
(3)加入适量水至药物粉末中;
(4)混匀后,手工或机器成型,得到水丸。
实施例12:桂枝12克、菖蒲10克、郁金10克、炙麻黄6克、细辛3 克、木香10克、檀香6克、炙甘草6克和丹参10克。
糊丸剂包括如下步骤:
(1)将上述原料药物混合在一起;
(2)将上述中药组分干燥后磨粉,药物粉末为60~100目为宜;
(3)加入适量淀粉糊或米糊至药物粉末中;
(4)混匀后,手工或机器成型,得到糊丸。
实施例13:桂枝10克、菖蒲20克、郁金20克、炙麻黄10克、细辛3 克、木香12克、檀香6克、炙甘草6克和紫河车6克。
胶囊剂包括如下步骤:
(1)将上述原料药物混合在一起;
(2)将上述中药组分干燥后磨粉,药物粉末为80~100目为宜;
(3)将药物粉末制粒,干燥;
(4)将药粒用机器灌装入胶囊,得到胶囊剂。
实施例14:桂枝12克、菖蒲15克、郁金15克、炙麻黄9克、细辛6 克、木香12克、檀香9克和炙甘草12克。
蜜丸包括如下步骤:
(1)将上述原料药物混合在一起;
(2)将上述中药组分干燥后磨粉,药物粉末为60~100目为宜;
(3)以药粉的重量按1∶1~1.5的比例称量蜂蜜,熬炼蜂蜜至中蜜;
(4)将药粉与中蜜混匀后,手工或机器成型,得到蜜丸。
实施例15:桂枝10克、菖蒲20克、郁金20克、炙麻黄10克、细辛3 克、木香10克、檀香10克和炙甘草10克。
膏方包括如下步骤:
(1)将上述原料药物混合在一起,切碎成适宜的片、段或磨成粗末;
(2)将上述中药组分混合并置于煎煮器内,加水湿润1~2小时,再加水煎煮,煎煮持续2~5小时,取出煎液用适宜滤器过滤,得到滤液;
(3)残渣加水继续煎煮,至煎液气味单薄,取出煎液备用;
(4)残渣压榨,榨出液与全部煎液混合,静置1~2小时,用滤器滤净;
(5)取上述滤液,置于蒸发锅中,浓缩至稠膏状,得到清膏;
(6)取与清膏等重量或倍量的蜂蜜加入清膏,得到膏方;
(7)装入无菌容器中密封。
临床试验研究
研究目的为观察本发明药物的临床疗效和安全性,病例来源于本院门诊及病房的心动过缓患者64例,经动态心电图明确诊断,且符合《实用心脏病学》(2016版 陈灏珠主编上海科学技术出版社)及《中药新药临床研究指导原则》(1995年)中相关的诊断标准。患者随机分为治疗和对照组各32例,治疗组男18例,女14例,年龄15~80岁,平均年龄(59.28±17.17)岁,其中冠心病5例,高脂血症4例,无心血管病 23例;对照组男15例,女17例,年龄(59.47±15.51)岁,其中冠心病4 例,高脂血症7例,无心血管病21例。对照组因未复诊脱落2例,按照意向性分析原则,采用SPSS22.0软件进行统计分析。两组患者性别、年龄、病情及疗前各指标等方面比较,差异无统计学意义(P>0.05),具有可比性。
治疗方案:治疗组服用本发明制备的中药颗粒剂,服用方法:每日早晚各一次,每次一格,150ml开水冲服,服用8周。
对照组服用心宝丸,组成为洋金花、人参、肉桂、附子、鹿茸、冰片、人工麝香、三七、蟾酥。药物产自广东太安堂药业(批号:国药准字Z44022728)。服用方法:5粒/次,3次/天,服用8周。
疗效评价标准:
观察指标:
服药前后各查一次24h动态心电图,观察总心搏、最慢心率、平均心率、最长RR间期及心率变异性指标SDNN、SDANN、PNN50、RMSSD 的变化,评价心动过缓的疗效;观察服药期间有无不良反应及对肝肾功能、血、尿、便常规的影响。
研究结果:
1.临床疗效比较:
治疗后,心动过缓疗效比较,治疗组显效13例,有效15例,无效4 例,总有效率87.5%;对照组显效4例,有效17例,无效11例,总有效率 65.6%,治疗组总有效率明显高于对照组(P<0.05)。中医证候积分比较,治疗组显效9例,有效20例,无效3例,总有效率90.6%;对照组显效3例,有效17例,无效12例,总有效率62.5%,治疗组优于对照组(P <0.05)。
治疗后两组患者心率24h动态心电图总心搏数、最慢心率及平均心率都明显提高,最长RR间期明显缩短,心率变异性指标SDNN、RMSSD 均明显降低,且治疗组提高总心搏次数、最慢心率,缩短长间歇,降低自主神经总张力指标SDNN、迷走神经张力指标PNN50、RMSSD的效果优于对照组,差异有统计学意义(P<0.05)。
表1:治疗后两组心动过缓疗效比较
表1
表2:治疗后两组中医证候积分比较
表2
表3:治疗后两组24h动态心电图心率指标比较
表3
表4:治疗后两组24h动态心电图心率变异性指标比较
组别 | SDNN(ms) | SDANN(ms) | PNN50(%) | RMSSD(ms) |
治疗组 | 149.95±33.81 | 161.49±40.57 | 20.03±12.93 | 82.52±40.81 |
对照组 | 175.27±45.50 | 157.25±46.04 | 27.92±15.60 | 111.75±63.55 |
P值 | 0.014 | 0.698 | 0.031 | 0.035 |
表4
2.不良反应比较:
治疗后两组患者血常规、肝肾功能、尿常规、便常规均未见异常,服药期间治疗组患者出现胃部不适1例(3.12%);对照组出现心慌加重 1例(3.12%),胃部不适2例(6.25%)。两组患者均无严重不良反应。
结果说明,本发明中药组合物治疗心动过缓效果显著,能够提高心率,降低迷走神经张力,平衡自主神经功能,且安全性良好,值得临床推广及应用。
病例:
病例1
于某,女,80岁,因“心率慢4年余”就诊,白天心率30-40次/分,夜晚30次/分。时胸闷痛,憋气,心烦,腹胀,双下肢轻度水肿,纳眠差。既往冠心病、高血压、糖尿病病史。拒绝安装起搏器。动态心电图示:窦性停搏,结性逸搏,结性心律,RR大于2.0s次数6402次,最长 RR间期6.94s,最慢心率16次/分,平均心率39次/分,总心搏55727次 /24h。予本发明中药组合物:桂枝10克、石菖蒲15克、郁金15克、炙麻黄12克、细辛3克、木香10克、檀香10克、丹参20克,炒酸枣仁30克等,每日一剂,水煎,分两份,早晚饭后1小时温服。服药2月后查动态心电图示:RR大于2.0s次数10次,最长RR间期2.20s,最慢心率38次/分,平均心率69次/分,总心搏次100759次/24h。胸闷痛、憋气诸症改善。
病例2
韩某,女,78岁,反复头晕4年,发作一过性晕厥2次,胸闷、憋气。既往“脑梗死”、“颈动脉斑块”、“下肢动脉斑块”病史。动态心电图示:窦性停搏,最长7.7s,大于2.5s次数73次,最慢心率28次/分,平均心率56次/分,总心搏79828次/24h,房早1062次/24h,室早108次/24h。经服本发明中药组合物:桂枝10克、石菖蒲15克、郁金15克、炙麻黄10 克、细辛6克、木香10克、檀香10克、丹参20克等,每日一剂,颗粒剂,分两份,早晚各一份。服药5个月后,头晕、胸闷、憋气愈,晕厥未发,复查动态心电图:窦性停搏,最长2.8s,大于2.5s次数2次,最慢心率38 次/分,平均心率64次/分,总心搏90644次/24h,房早2532次/24h,室早10次/24h。
病例3
陈某,女,15岁,体检发现停搏及传导阻滞,时头晕、胸闷。动态心电图示:窦性停搏,最长2.6s,大于2.0s次数71次,最慢心率26次/ 分,平均心率59次/分,总心搏68238次/24h,房早43次/24h,一度房室传导阻滞,二度一型房室传导阻滞,二度二型房室传导阻滞,高度房室传导阻滞,三度房室传导阻滞,过缓的交界性逸搏,室性逸搏,可见窦性夺获。经服本发明中药组合物:桂枝9克、石菖蒲12克、郁金12 克、细辛3克、木香9克、檀香6克、炙麻黄9克、丹参12克、玄参12克等,每日一剂,颗粒剂,分两份,早晚各一份。服药半年后,诸症痊愈,已无停搏,坚持服药一年后复查动态心电图:停搏0,最慢心率37次/ 分,平均心率79次/分,总心搏101814次/24h,二度房室传导阻滞。
以上显示和描述了本发明的基本原理和主要特征及本发明的优点。应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明基本原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也视为本发明的保护范围。
Claims (8)
1.一种治疗心动过缓的中药组合物,其特征在于,包括以下重量份的各组分,桂枝10~20份,菖蒲10~30份,郁金10~30份,炙麻黄6~15份,细辛2~6份,木香6~20份,檀香3~10份和炙甘草6~20份。
2.根据权利要求1所述的一种治疗心动过缓的中药组合物,其特征在于,所述的桂枝10份,菖蒲20份,郁金20份,细辛3份,木香10份,檀香10份,炙麻黄10份和炙甘草10份。
3.根据权利要求1或2所述的一种治疗心动过缓的中药组合物,其特征在于,还包括丹参10~30份,玄参10~20份,阿胶10~20份、紫河车6~10份。
4.根据权利要求4所述的一种治疗心动过缓的中药组合物,其特征在于,在该中药组合物内加上药学上可接受的赋形剂制成药学上的常规制剂。
5.根据权利要求4所述的一种治疗心动过缓的中药组合物,其特征在于,所述赋形剂位崩解剂、润滑剂或黏合剂中的一种或多种,所述药学上的常规制剂优选汤剂、丸剂、散剂、膏方、胶囊或片剂的口服制剂。
6.根据权利要求1至3任意一项一种治疗心动过缓的中药组合物在制备治疗心动过缓的药物中的应用。
7.一种制备如权利要求1~3所述的一种治疗心动过缓的中药组合物的方法,其特征在于,包括如下步骤:
(1)将各组分按照重量比称重;
(2)将步骤(1)中混合的各组分混合并置于容器内,加水没过药面,浸泡20~30分钟;
(3)用文火煎煮,至煮沸后再继续煎煮20~30分钟,共煎煮三次;
(4)将三次煎液合并、过滤,得到汤剂。
8.根据权利要求7所述的方法,其特征在于,所述的步骤(3)中,煎煮时间为25分钟。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910474592 | 2019-06-03 | ||
CN2019104745923 | 2019-06-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110339323A true CN110339323A (zh) | 2019-10-18 |
Family
ID=68180256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910679630.9A Pending CN110339323A (zh) | 2019-06-03 | 2019-07-26 | 一种治疗心动过缓的中药组合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110339323A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111529659A (zh) * | 2020-04-01 | 2020-08-14 | 王玉梅 | 治疗缓慢性心律失常的中药组合物及其制备方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101559197A (zh) * | 2008-04-17 | 2009-10-21 | 韩杰 | 一种治疗心动过缓的中药组合 |
CN102698222A (zh) * | 2012-05-18 | 2012-10-03 | 廖天源 | 一种治疗心动过缓的药物及其制备方法 |
CN107929644A (zh) * | 2017-12-12 | 2018-04-20 | 汤阴县瑞星生物有限公司 | 一种治疗窦性心动过缓的中药组合物及其制备方法 |
CN111529659A (zh) * | 2020-04-01 | 2020-08-14 | 王玉梅 | 治疗缓慢性心律失常的中药组合物及其制备方法和应用 |
-
2019
- 2019-07-26 CN CN201910679630.9A patent/CN110339323A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101559197A (zh) * | 2008-04-17 | 2009-10-21 | 韩杰 | 一种治疗心动过缓的中药组合 |
CN102698222A (zh) * | 2012-05-18 | 2012-10-03 | 廖天源 | 一种治疗心动过缓的药物及其制备方法 |
CN107929644A (zh) * | 2017-12-12 | 2018-04-20 | 汤阴县瑞星生物有限公司 | 一种治疗窦性心动过缓的中药组合物及其制备方法 |
CN111529659A (zh) * | 2020-04-01 | 2020-08-14 | 王玉梅 | 治疗缓慢性心律失常的中药组合物及其制备方法和应用 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111529659A (zh) * | 2020-04-01 | 2020-08-14 | 王玉梅 | 治疗缓慢性心律失常的中药组合物及其制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102772704B (zh) | 老年病药物 | |
CN102813839B (zh) | 治疗血管神经性头痛的复方药物 | |
CN102335330A (zh) | 一种治疗失眠的中药组合物 | |
CN102166278A (zh) | 一种治疗小儿类风湿性关节炎的中药组合物及其制备方法 | |
CN102114231B (zh) | 一种治疗心律失常的药物 | |
CN104274754A (zh) | 一种治疗小儿遗尿的中药组合物及其制备方法 | |
CN103919910A (zh) | 一种治疗冠心病的药物 | |
CN106474356A (zh) | 一种通梗化栓的药物及其制备方法 | |
CN102579610A (zh) | 一种治疗脑出血的中药组合物及其制备方法 | |
CN103007159B (zh) | 校正胰岛功能的中药制剂 | |
CN110339323A (zh) | 一种治疗心动过缓的中药组合物及其制备方法和应用 | |
CN102327436A (zh) | 一种治疗经行浮肿的中药组合物 | |
CN102283940A (zh) | 一种治疗心悸的中药制剂 | |
CN102908396B (zh) | 一种具有促进睡眠作用的中药组合物及其制备方法 | |
CN103798472B (zh) | 一种保健茶及保健养生制剂 | |
CN102988747B (zh) | 一种三刺降三高的冲剂及其制备方法 | |
CN111529659A (zh) | 治疗缓慢性心律失常的中药组合物及其制备方法和应用 | |
CN101897940A (zh) | 一种抗疲劳的中药配方及其制备方法 | |
CN109999098A (zh) | 一种用于治疗肿瘤相关性睡眠障碍的中药外用制剂 | |
CN104666689A (zh) | 一种治疗高血压的药物 | |
CN103736027A (zh) | 一种治疗失眠的中药组合物 | |
CN102961540A (zh) | 一种治疗冠心病的药物及其制备方法 | |
CN107260978A (zh) | 一种中药组合物及其制备方法和用途 | |
CN100406035C (zh) | 一种治疗腰椎间盘突出症的中药制剂 | |
CN106822852A (zh) | 治疗冠心病的药物组合物、其制备工艺及用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20191018 |
|
WD01 | Invention patent application deemed withdrawn after publication |